Product Information
QBRELIS 1 MG/ML SOLUTION is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $4.4974 per ML under NDC 52652300101. Its NADAC has been published 211 times since Sep 21, 2022.
FDA first approved this application on Jul 29, 2016. Its Orange Book therapeutic-equivalence code is AA.
The High Outlier badge above means this manufacturer's average price in the lisinopril market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 mg/mL
Manufacturer
Azurity Pharmaceuticals Inc.NDC
52652300101
Classification
Brand
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LISINOPRILApproval Type
New Drug (NDA)
FDA Application
NDA208401FDA Approved
7/29/2016
TE Code
AA
On Market Since
8/29/2016
Pharmacological Classes
Price Statistics
The NADAC for QBRELIS 1 MG/ML SOLUTION has been published 211 times since Sep 21, 2022, and over the history we have for it it has risen 31.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.4974 per ML |
|---|---|
| All-time high | $4.4974 (Sep 30, 2026) |
| All-time low | $3.4237 (Sep 21, 2022) |
| 52-week high | $4.4974 |
| 52-week low | $4.3447 |
| Median price | $4.0365 |
| Average price | $4.0800 |
| Largest weekly change | +9.8% (Jan 4, 2023) |
| Weeks tracked | 211 |
| Tracking since | Sep 21, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lisinopril market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lisinopril market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QBRELIS 1 MG/ML SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for QBRELIS 1 MG/ML SOLUTION, manufactured by Azurity Pharmaceuticals Inc., is $4.4974 per ML (NDC 52652300101), effective Sep 30, 2026.
How has the price of QBRELIS 1 MG/ML SOLUTION changed over time?
Over the history we have for it, the NADAC for QBRELIS 1 MG/ML SOLUTION has risen 31.4%. It has been tracked across 211 weekly CMS publications since Sep 21, 2022.
What are the highest and lowest recorded NADAC prices for QBRELIS 1 MG/ML SOLUTION?
Since Sep 21, 2022, the NADAC for QBRELIS 1 MG/ML SOLUTION has ranged from a low of $3.4237 (Sep 21, 2022) to a high of $4.4974 (Sep 30, 2026), with a median of $4.0365 per ML.
Are there cheaper alternatives to QBRELIS 1 MG/ML SOLUTION?
No other NADAC-published product currently shares the active ingredient and strength of QBRELIS 1 MG/ML SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QBRELIS 1 MG/ML SOLUTION?
QBRELIS 1 MG/ML SOLUTION (NDC 52652300101) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.